相关实验视频

Updated: Jul 29, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

脂质修饰药物和其他药物的对脂蛋白的影响 (a) 水平-潜在的临床影响

Amalia Despoina Koutsogianni¹, George Liamis¹, Evangelos Liberopoulos²

¹Department of Internal Medicine, Faculty of Medicine, University of Ioannina, 45110 Ioannina, Greece.

Pharmaceuticals (Basel, Switzerland)

|May 27, 2023

概括

脂蛋白 (Lp) 与心血管疾病有关. 虽然他类药物可能会增加Lp(a),但PCSK9抑制剂和ASO和siRNA等新疗法在降低Lp(a) 水平方面表现有前途.

科学领域:

心血管医学心血管医学
药理学药理学是指药理学的学科.
脂质学脂质学是指脂质学.

背景情况:

升高的脂蛋白 (Lp) 水平与心血管疾病 (CVD) 风险增加和动脉狭窄症有关.
像他类药物这样的标准降脂疗法可以矛盾地增加Lp (a) 水平.
蛋白转化酶亚素/素9型 (PCSK9) 抑制剂表明Lp(a的减少,尽管临床意义需要进一步阐明.

研究的目的:

审查已建立和新兴的脂质修饰药物对Lp (a) 度的影响.
探索非脂质修饰药物对Lp (a) 水平的影响.
通过药物干预来调节Lp (a) 水平的临床影响.

主要方法:

在MEDLINE,EMBASE和CENTRAL数据库中进行系统文献搜索,截至2023年1月28日.
对研究不同药物类别对Lp (a) 水平的影响的分析.
综合证据关于已确立和新的治疗方法Lp(a) 管理.

主要成果:

类他类药物通常显示Lp (a) 水平略有增加.
已观察到PCSK9抑制剂降低了Lp (a) 度.
新兴疗法,包括反意义寡核酸 (ASOs) 和小干扰RNA (siRNAs),专门设计用于减少Lp(a),正在进行结果试验.

结论:

针对Lp(a) 的药物干预正在发展,新药显示出显著的Lp(a) 降低潜力.
了解药物诱导的Lp变化 (a) 对于控制心血管风险至关重要.
进一步的临床试验至关重要,以证实降低Lp的心血管益处.

关键词:

PCSK9 抑制剂的使用.反感的寡核化物.脂蛋白 (a) 是一种蛋白质小的干扰RNAs可以干扰.类药物类药物类药物

更多相关视频

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Factors Affecting Protein-Drug Binding: Drug-Related Factors

Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...